Vanessa
Roldan Schilling
Catedraticos de Universidad Vinculados H.V.Arrixaca
![Foto de Vanessa](/img/uploaded/aab593d7615a80d42da1c23d7d2bc16b.jpeg)
![Foto de Pfizer (United States)](/img/noimage_org.png)
Pfizer (United States)
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Pfizer (United States) (3)
2022
-
Characteristics and management of patients with stroke and major hemorrhagic episodes with atrial fibrillation under vitamin K antagonist therapy. EVENTHO study
Medicina Clinica, Vol. 159, Núm. 8, pp. 366-371
2017
-
Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary
European Heart Journal, Vol. 38, Núm. 27, pp. 2137-2149
2016
-
A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation
Cardiology and Therapy, Vol. 5, Núm. 2, pp. 171-186